Hero image with Pittsburgh background https://pittplusme.org/study/666

We're sorry. This study is closed and no longer recruiting participants.

STUDY BASICS

Healthy teens ages 13-17, along with a parent or sibling who has a history of a mood or psychotic disorder, are needed for a research study to understand how teens might develop mental health problems. The study involves an interview and questionnaire, computer tasks and brain imaging. Compensation provided.


STUDY PURPOSE

The purpose of this study is to understand how mood changes and develops over time and how it affects the development of problems like depression, schizophrenia or bipolar disorder.


COULD THIS STUDY BE RIGHT FOR YOUR CHILD?
  • Between ages of 13 and 17
  • Have a parent or sibling diagnosed with major depressive disorder, bipolar disorder or schizophrenia
  • Parent or sibling must be willing to participate as well

WHAT PARTICIPANTS CAN EXPECT

This study involves 3 in-person visits conducted over 3 years and online questionnaires. Visits include computer tasks, interview and fMRI scan. The fMRI is an imaging technique that measures and maps brain activity. It does not involve radiation and is non-invasive.


IRB: STUDY20050116A
- Development of Anhedonia during Adolescence

RESEARCH AREAS:
  Healthy Child

PHONE NUMBER: 1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In

INTERESTED?

Visit https://pittplusme.org/study/666 and click on "I'm Interested" or call 1-866-438-8230.


LEARN MORE

PittPlusMe.org
1-866-438-8230
PittPlusMe@pitt.edu
@PittPlusMe
@PittPlusMe

MEET THE RESEARCHER


Erika Forbes

Erika E. Forbes, PhD, is associate professor of psychiatry, psychology, and pediatrics at the University of Pittsburgh. Dr. Forbes is a specialist in the field of depression, especially regarding reward-related brain functioning in adolescents. Her research has been published in a number of leading publications. She has received awards and honors from the University of Pittsburgh, American College of Neuropsychopharmacology, National Alliance for Research on Schizophrenia and Depression, and the National Institute of Health.